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Abstract Zolpidem produces paradoxical recovery of speech, cognitive and motor functions in 
select subjects with severe brain injury but underlying mechanisms remain unknown. In three diverse 
patients with known zolpidem responses we identify a distinctive pattern of EEG dynamics that 
suggests a mechanistic model. In the absence of zolpidem, all subjects show a strong low frequency 
oscillatory peak ∼6–10 Hz in the EEG power spectrum most prominent over frontocentral regions and 
with high coherence (∼0.7–0.8) within and between hemispheres. Zolpidem administration sharply 
reduces EEG power and coherence at these low frequencies. The ∼6–10 Hz activity is proposed 
to arise from intrinsic membrane properties of pyramidal neurons that are passively entrained across 
the cortex by locally-generated spontaneous activity. Activation by zolpidem is proposed to arise from 
a combination of initial direct drug effects on cortical, striatal, and thalamic populations and further 
activation of underactive brain regions induced by restoration of cognitively-mediated behaviors.
DOI: 10.7554/eLife.01157.001
Introduction
Induced recovery of spoken language, cognitive and motor functions following administration of 
zolpidem, a gamma-aminobutyric acid type A (GABA-A) subclass alpha 1 receptor positive allosteric 
modulator (Hambrecht-Wiedbusch et al., 2010) in severely brain-injured subjects with disorders of 
consciousness are rare, but well documented (Clauss et al., 2000; Brefel-Courbon et al., 2007; 
Cohen and Duong, 2008; Shames and Ring, 2008; Whyte, 2009; Hall et al., 2010). In some instances, 
behavioral improvement spans the range from only limited signs of conscious awareness to recovery 
of conversant language, ambulation and coordinated motor activity within an hour of administration 
of the medication. However, the mechanisms underlying this phenomenon are poorly understood. 
Because of the rarity of the phenomenon, as well as logistical impediments, only a small number of 
prior studies have characterized zolpidem-induced physiological changes these patients (Clauss et al., 
2000; Clauss and Nel, 2006; Brefel-Courbon et al., 2007; Cohen and Duong, 2008; Shames and 
Ring, 2008; Whyte, 2009; Hall et al., 2010; Nyakale et al., 2010).
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Here we investigate the detailed neurophysiological changes present in the resting electroenceph-
alogram (EEG) in three patient subjects with such paradoxical behavioral facilitation in response to 
zolpidem and widely disparate underlying etiologies of severe brain injury and disorders of conscious-
ness (severe hypoxic-ischemic encephalopathy, severe diffuse axonal injury and multifocal ischemic 
injuries). All subjects were more than 12 months post-injury and had histories of zolpidem response 
and regular usage of the drug for behavioral facilitation. Despite the wide differences in the etiology 
of brain injury across subjects, quantitative analysis of resting EEG dynamics reveals a striking com-
monality of spectral features in the absence of zolpidem, and stereotyped changes in these spectral 
quantities when the drug is administered.
Based on the specific spectral changes observed, we propose a unifying biological mechanism 
accounting for the observed dynamical features of the resting brain state and the changes in brain 
dynamics linked with zolpidem-induced behavioral facilitation.
Further, our interpretative model implies a mechanistic basis for the differences in EEG dynamics 
associated with the zolpidem response in subjects with global brain injury and those observed in 
a stroke patient (Hall et al., 2010), and offers predictions for distinguishing these two mechanisms.
Results
Behavioral effects of zolpidem in patient subjects
The three patient subjects were drawn from a wider observational study of recovery after severe brain 
injuries based on their history of behavioral facilitation with zolpidem; all subjects received zolpidem on 
a regular basis prior to this study (see ‘Methods’ Clinical Histories). As a first step, the zolpidem-induced 
behavioral responses were confirmed by formal assessments of behavior ON and OFF drug by the research 
teams (‘Methods’). For subjects 1 and 3, this assessment was made with the Coma Recovery Scale-Revised, 
a well-established, standardized rating scale for patients with disorders of consciousness (Giacino et al., 
2004; Seel et al., 2010); the CRS-R captures variations in cognitively-mediated behaviors up to a level 
of reliable and consistent communication through speech or gesture. For subject 2, baseline behavior 
was at ceiling for the CRS-R, so behavioral assessment was carried out by structured clinical observations.
eLife digest Some individuals who experience severe brain damage are left with disorders 
of consciousness. While they can appear to be awake, these individuals lack awareness of their 
surroundings and cannot respond to events going on around them. Few treatments are available, 
but a minority of patients show striking improvements in speech, alertness and movement in response 
to the sleeping pill zolpidem.
Although the idea of a sleeping pill increasing consciousness is paradoxical, it is possible that in 
patients with impaired consciousness, zolpidem reduces the activity of an area of the brain that 
would otherwise inhibit activity in other regions of the brain. However, the precise mechanisms by 
which zolpidem increases consciousness in these patients, and the reasons why only a minority of 
individuals respond, are unknown.
Now, Williams et al. have used electrodes attached to the scalp to measure changes in brain 
activity in three patients known to respond to zolpidem. These measurements showed that before 
the drug was taken, there were two important differences between the brain activity of the patients 
and that of healthy subjects: first, the patients showed brain waves of a lower frequency than any 
seen in healthy subjects; second, these brain waves were much more synchronized than brain activity 
in healthy individuals. After taking zolpidem, this synchronicity was reduced and all of the patients 
also showed an increase in higher frequency brain waves.
Based on the effects of zolpidem on electrical activity throughout the brain, Williams et al. propose 
a new model to explain the therapeutic action of the drug in some minimally conscious patients. If the 
correlation between brain waves and zolpidem response holds up in future studies, this relation could 
be used to predict which patients might benefit from the drug. A better understanding of these 
processes should also help us to understand, diagnose and develop new treatments for disorders of 
consciousness.
DOI: 10.7554/eLife.01157.002
Human biology and medicine | Neuroscience
Williams et al. eLife 2013;2:e01157. DOI: 10.7554/eLife.01157 3 of 22
Research article
All three subjects showed reproducible behavioral improvements following zolpidem. Figure 1 
shows CRS-R ratings (total and subscale) for Subject 1, following five doses (red lines) of the medication 
(four doses with concomitant video/EEG recordings studied here are labeled on Figure with red 
arrows). For assessments in the OFF-drug period (the first assessment, which followed a 62-hr 
washout, and at every time point that was at least 4 hr after zolpidem administration), the total CRS-R 
score ranged from 10–15. After each administration of zolpidem, the CRS-R score rose to ceiling (total 
score = 23). This change in CRS-R total score reflects improvements in all subscales, including recovery 
of functional movements, consistent communication, and elements of executive function. Additional 
changes not captured by this psychometric instrument included recovery of fluent verbal communication, 
writing and complex organized movements such as assembling block structures to match arbitrary 
configurations (see ‘Clinical histories’ for further clinical details and additional neuropsychological 
assessments). As seen in Figure 1, maximal total CRS-R scores consistently appeared within 1 hr after 
drug administration. The period during which the maximal CRS-R score was maintained appeared to 
Figure 1. Behavioral changes associated with zolpidem doses in Subject 1. Subject 1 demonstrated only a limited 
range of behaviors in the baseline (OFF drug) state including automatic motor responses (e.g., reaching to a hand 
extended for a handshake, CRS-R motor subscore 5), oro-motor behaviors (e.g., opening mouth when presented 
with a spoon CRS-R oro-motor subscore 2 or biting a tongue depressor, CRS-R oro-motor subscore 1), localization 
of sound with head turning (CRS-R auditory subscale score 2), and reaching to objects (CRS-R visual subscale score 4). 
During all baseline assessments the patient demonstrated no evidence of command following or a communication 
system (CRS-R communication subscale score 0). Across three assessments of baseline behavior OFF drug after 
overnight periods and a 62 hr washout period at the onset of the study total CRS-R scores ranged from 10–15 
reflecting a lack of goal-directed behaviors, evidence of any communication systems either verbal or gestural, nor 
consistent response to command following. Across two assessments of baseline behavior at least 4 hr after a prior 
dose of zolpidem within a day (reflecting typical duration of action of the medication) maximal total CRS-R scores 
of 18 reflected evidence of command following with inaccurate communication and higher level motor function 
(CRS-R subscale motor score of 6) or consistent auditory command following (CRS-R auditory subscale score of 4). 
Compared with these baseline behavioral assessments, consistent achievement of a maximum possible total CRS-R 
scores of 23 was obtained during all ON drug periods reflecting a state in which the patient consistently demonstrated 
behavioral levels not captured by this psychometric instrument including recovery of consistent communication, 
fluent verbal communication, writing and complex organized movements (see ‘Clinical histories’ for further 
clinical details and additional neuropsychological assessments). As seen in graph, a maximal total CRS-R scores 
consistently appeared following drug administration within approximately 1 hr and had a variable duration of 
maintenance with second daily dose of the medication showing extended time periods of maximal total scores. Red 
arrows indicate zolpidem doses for which accompanying EEG data were available for analyses. Videos 1 and 2 
illustrate aspects of the examinations to show correspondence of numerical ratings and behavior.
DOI: 10.7554/eLife.01157.003
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be longer for the second dose of the day (doses 
two and four) than the corresponding first dose 
(doses one and three).
For subject 2, the behavioral baseline in the 
OFF drug state included consistent communica-
tion and command-following, and the CRS-R was 
at ceiling. As documented by structured clinical 
observations following nine doses, this patient’s 
zolpidem-induced behavioral facilitation included 
marked improvements in oro-motor control of 
chewing and swallowing, and increased verbal 
fluency. Additionally, there was a suppression of 
a coarse tremor and restoration of goal-directed 
fine motor-control of the dominant right arm and 
hand. This subject had received three daily doses 
of zolpidem for five years at the time of the study; 
an earlier report of zolpidem induced behavioral 
facilitation in this subject from the third year of 
use of the medication (Clauss and Nel, 2006) indi-
cated a shift from a level II Rancho Los Amigos 
Cognitive Score to a level VI-VII indicating that at 
baseline purposeful vocalization was not observed 
in the OFF drug state at that time.
For subject 3, the behavioral baseline was char-
acterized by reproducible responses to command, 
visual fixation, automatic motor responses, intelli-
gible verbalization and intentional communication. 
These behavioral responses, however, could only 
be elicited with vigorous arousal enhancing maneu-
vers. After zolpidem administration on a single 
formal assessment, CRS-R score increased from 
15 to 16. This one-point change reflected a change 
in the CRS-R arousal subscale score from 1 to 2: 
a shift from a state that required constant stimula-
tion to maintain arousal to a state characterized 
by spontaneous eye-opening and behavioral 
responsiveness. Other CRS-R subscale scores did 
not change but no longer depended on external 
stimulation to elicit responsiveness. In addition, 
the subject also showed increased alertness (as 
judged by orientation to sensory stimuli) and 
agitated movements, with an increase in speech 
rate and words that were subjectively rated as more 
intelligible (see ‘Methods’ Clinical Histories).
Effects of zolpidem administration 
on the EEG power spectrum
To characterize changes in spontaneous brain 
dynamics associated with zolpidem administration, we analyzed the EEG around the times of zolpidem 
administration. Subjects 1 and 2 were studied over several days in a hospital setting; Subject 3’s 
evaluation was limited to assessment of a single dose of zolpidem while at home (‘Methods’). We begin 
by comparing the EEG in the hour preceding and following zolpidem administration, and then consider 
its further evolution in time.
Figure 2 shows results from the frontal midline electrode pair Fz-Cz for all three subjects. Prior 
to zolpidem administration, each subject’s data demonstrates a peak of power in the range 6–10 Hz. 
In all cases, this peak is sharply attenuated 1 hr following drug administration, and there is an increase 
Video 1. Demonstration of CRS-R Motor subscale 
Subject 1 during off zolpidem state. Prior to zolpidem 
administration subject is tested with two common 
objects (comb and spoon) and asked to demonstrate 
their use. While able to hold each object he is unable 
to demonstrate their use. This level of behavior 
corresponds to a 5 on the CRS-R Motor subscale. 
Note resting tremor of right hand.
DOI: 10.7554/eLife.01157.004
Video 2. Demonstration of CRS-R Motor subscale 
Subject 1 following zolpidem administration. Short 
legend: Following zolpidem administration subject is 
again tested with two common objects (comb and 
spoon) and asked to demonstrate their use. He is now 
able to demonstrate the use of each object. This level 
of behavior corresponds to a 6 on the CRS-R Motor 
subscale. Note that subject’s posture has changed and 
that the right hand is used.
DOI: 10.7554/eLife.01157.005
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in power in the range ∼15–30 Hz (p<0.05 by a 
z-statistic, the Two Group Test (Bokil et al., 2007), 
see ‘Methods’ for approach to significance testing, 
Figure 3—figure supplement 1; Tables 1 and 2). 
Figure 2—figure supplement 1 shows that the 
changes in spectral shape do not represent a 
‘performance confound’. Specifically, we deter-
mined EEG power spectra only from periods in 
which the patient was at rest and not interactive 
with persons or objects in their environment and 
compared this with the power spectra obtained 
during active interactions with people at the 
bedside. The level of environmental stimulation 
did not influence the spectrum, and the zolpidem 
effect of Figure 2 was similarly present for both 
periods of either low or high levels of environmen-
tal stimulation.
Figure 3, Figure 3—figure supplement 1; 
Tables 1 and 2 show that in each patient, the 
changes in spectral shape following zolpidem 
administration are widely distributed across the 
electrode array.
Although some individual channels show addi-
tional specific features (e.g., a low frequency peak 
at ∼12 Hz in channel pair C4-CP2 in Subject 1), 
the low frequency oscillations ∼6–10 Hz are dif-
fusely present across brain regions in the base-
line condition in all subjects, and absent following 
zolpidem. Similarly, widely-distributed increases 
in ∼15–30 Hz power are observed after zolpidem 
administration in all three subjects (Figure 3).
Analysis of responses to multiple drug admin-
istrations was carried out in Subject 1 (four admin-
istrations) and Subject 2 (five administrations). 
Figure 4 shows the spectra at Fz-Cz in order of 
decreasing washout time of the prior zolpidem 
dose ( Tables 1 and 2). Consistent with the data 
shown in Figures 2 and 3, all transitions show a 
decrease in power at 6–10 Hz and an increase 
from 15–30 Hz following drug administration 
(p<0.05). In both subjects, the low-frequency peak 
is least prominent when prior washout period is 
shortest, suggesting that there is a carry-over 
effect at these dosing intervals.
Further analysis of changes in the power 
spectrum across different washout intervals after 
each dose revealed three additional findings: 
(1) a clear distinction between changes in resting 
low frequency oscillations present over anterior 
(frontocentral-temporal) and posterior (centro-parietal-occipitotemporal) channels, (2) a common 
average resting low frequency peak across anterior channels, and (3) a consistent increase in the 
average center frequency of the posterior but not the anterior EEG channels with shorter dosing 
intervals. Comparison of the anterior and posterior channels in both subjects reveal a consistent 
finding of lower resting average low frequency in anterior channels typically ∼7.4 Hz. In Table 1 , the 
average center frequency for anterior EEG channels in Subject 1 ranges from 7.1 Hz to 7.4 Hz, while 















































Figure 2. Power spectra estimated from midline EEG 
channel Fz-Cz recordings. Power spectra from all three 
subjects (mean and 95% confidence intervals). Red: 
average spectral power in the hour prior to each zolpidem 
dose. Blue: 20–60 min after the zolpidem dose. Narrow, 
low frequency spectral peaks are apparent in the pre-drug 
state that are attenuated in the hour post-dose. Beta 
range peaks (20–30 Hz) are apparent in all post-drug 
spectra. Changes in ∼6–10 Hz peak between conditions 
are significant by two-group test (see ‘Methods’; 
Table 1).
DOI: 10.7554/eLife.01157.006
The following figure supplements are available for 
figure 2:
Figure supplement 1. Analysis of EEG segments 
obtained during ON and OFF drug periods from Subject 
1’s second zolpidem administration (cf. Figure 1; Table 1) 
subdivided according to periods of low and high levels 
of environmental stimulation, a distinction based on 
detailed review of the simultaneously recorded video. 
DOI: 10.7554/eLife.01157.007
Human biology and medicine | Neuroscience
Williams et al. eLife 2013;2:e01157. DOI: 10.7554/eLife.01157 6 of 22
Research article
Table 1. Relationship of low frequency peak in OFF zolpidem baseline and time interval between doses
SUBJECT 1 center frequency for low frequency peak in hour prior to dose across channels and 
transitions
Baseline 1 Significant Baseline 2 Significant Baseline 3 Significant Baseline 4 Significant
(62 hr off  
drug) On vs off
(17 hr off  
drug) On vs off
(9 hr off  
drug) On vs off
(5 hr off  
drug) On vs off
Channel Pairs 9:30AM, 1st suppression 12:00PM, 1st suppression 6:30PM, 2nd suppression 5:00PM, 2nd suppression
Fpz Fp1 7.7 * 7.3 * 7.7 * – –
Fpz Fp2 7 * 7.3 * 7.3 * – –
Fp1 F3 7.7 * 7.3 * 7.3 * 7 *
Fp2 F4 7.3 * 7.3 * 7.3 * 6.3 *
F1 FC1 7.3 * 7.7 * 7.3 * 7 *
FC1 C3 7.3 * 7.7 * 7 * 7 *
FC2 C4 – – 7.3 * 7 * – –
F3 FC1 6.7 * 7.3 * 6.7 * 7.3 *
F4 FC2 7.3 * 7.7 * 7 * 7.7 *
F2 FC2 7.3 n.s. 7.7 * 7 * 7 n.s.
Fp1 AF7 6.3 * 7.7 * 7.3 * 7 *
Fp2 AF8 7.3 * 7.3 * 7.3 * – –
AF7 F7 6.7 * 7.3 * 7.3 * 6.3 *
AF8 F8 7 * 7.3 * 7.3 * – –
F7 FC5 6.7 * 7.3 * 7.3 * 6.3 *
F8 FC6 7.7 * 7.3 * 7.3 * 8.3 n.s.
FC5 T3 6 * 7.3 * 7.3 * 7.3 *
FC6 T4 7.3 n.s. 7.3 * – – – –
T3 CP5 – – 7.3 * 7.3 * 9.7 *
T4 CP6 7.7 * 7.3 * 7.7 n.s. 9.3 *
C3 CP1 – – 7.7 * 7 * 7 *
C4 CP2 – – 7.7 * 7.3 * 7 *
Fz Cz 7.3 * 7.7 * 7 * 7 *
Anterior Channels
 Average  
  Center Freq
7.1 7.4 7.2 7.3
 Standard  
  Deviation
0.5 0.2 0.2 1.0
T5 PO7 – – 7.3 * 7.3 * 6.7 n.s.
T6 PO8 7.7 * 7.3 * 7.7 * 11 *
CP1 P3 7.7 * 7.7 * 6.7 * 6.7 *
CP6 T6 7.7 * 8.3 * – – 8 n.s.
CP2 P4 7.3 n.s. 8 * – – 9 n.s.
CP5 T5 – – 7.7 * 7.3 * 9.7 *
P3 O1 7.3 * 7.7 * 7.3 * 9 *
P4 O2 – – 8 * – - – –
PO7 O1 7.3 * 7.3 * 7.7 * 9 *
PO8 O2 7.7 * 7.7 * 7.3 * - –
Cz Pz – – 7.7 * 7 * 7 *
Table 1. Continued on next page
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difference for anterior and posterior EEG channels is seen in Table 2 for Subject 2; for this subject, 
anterior EEG channels show an average center frequency of ∼7.4 Hz for four of the five measured 
baselines , with the notable exception of the second baseline measurement. The second baseline 
measurement in Subject 2 occurred early in morning (8:30AM) and may reflect an independent influence 
of arousal state, as a similar effect of increased baseline 15–30 Hz power is seen for this pre-dose 
baseline (refer to Figure 4 and discussion below). Posterior EEG channels in Subject 2 show an average 
center frequency range from 8.0 Hz to 9.4 Hz.
Tables 1 and 2 show, in order of decreasing dosing (washout) interval, the average center fre-
quency of low frequency peaks in the baseline spectral power across EEG channels for Subjects 1 
and 2 prior to each administration of zolpidem. For the longest washout intervals compared to the 
shortest, the baseline spectral peaks appear at lower frequencies across all channels for both 
Subjects 1 and 2 (Tables 1 and 2). For the shortest washout intervals (Tables 1 and 2), however, 
the posterior channels demonstrate a persistent shift in the average center frequency suggesting 
a carry-over effect for these regions of the brain. For example, in the baseline prior to dose four 
for Subject 1 several EEG electrode derivations show an increase in the baseline low frequency 
peak including an ∼11 Hz peak arising posteriorly in channel pair T6–PO8; for Subject 2 an 11 Hz 
peak is similarly seen in their 4 and 5 hr washout baselines in the T5–O1,T6–O2 and T3–T5 channel 
pairs.
There are other differences between the spectral changes during the individual drug administra-
tions, but their interpretation is unclear because of the limited number of drug administrations that 
we were able to study. In some instances increased power in the ∼15–30 Hz range is also apparent 
before and after the drug administration. This variation is substantial and suggests a fluctuation in 
the baseline state possibly linked to differences in arousal state or other factors not controlled for in 
this observational study. For Subject 2, a marked change in the power spectrum in the ∼15–30 Hz 
range is limited primarily to the first dose which followed a 20 hr washout period and was received 
late in the afternoon (4:30 PM), suggesting that the regular dosing schedule in this subject of three 
SUBJECT 1 center frequency for low frequency peak in hour prior to dose across channels and 
transitions
Baseline 1 Significant Baseline 2 Significant Baseline 3 Significant Baseline 4 Significant
(62 hr off  
drug) On vs off
(17 hr off  
drug) On vs off
(9 hr off  
drug) On vs off
(5 hr off  
drug) On vs off
Channel Pairs 9:30AM, 1st suppression 12:00PM, 1st suppression 6:30PM, 2nd suppression 5:00PM, 2nd suppression
CPz POz 7.3 n.s. – – 6.7 * 6.7 *
POz Oz 7.7 * 7.3 * 7.3 * – –
Posterior Channels
 Average  
  Center Freq
7.5 7.7 7.2 8.3
 Standard  
  Deviation
0.2 0.3 0.3 1.5
Average across all
 Average  
  Center Freq
7.3 7.5 7.2 7.7
 Standard  
  Deviation
0.4 0.3 0.3 1.2
Table 1 shows average center frequency of low frequency peak at∼6–10 Hz, if present, across all channels for Subjects 1 in relation to time off zolpidem 
prior to 1 hr baseline EEG measurements and clock time of each dose. In both patients, shorter zolpidem dosing intervals are associated with 
higher center frequencies across posterior but not anterior EEG channels. Similarly, an increased standard deviation of the measurement is observed as 
interval between doses is shorter for the posterior EEG channel measurements. Of note, for both subjects, anterior EEG channel pre-zolpidem dose baselines 
revealed a consistent∼7.4 Hz average center frequency with a small standard deviation. The consistency of these findings despite the wide difference in 
their underlying etiologies of injury support the proposed common cellular and circuit mechanism; the correspondence of the∼7.4 Hz peak and 
intrinsic oscillation frequency of neocortical Layer V cells (Silva et al., 1991) also support this model.
DOI: 10.7554/eLife.01157.008
Table 1. Continued
Human biology and medicine | Neuroscience
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doses per day may produce carry-over effects that diminish once the subject is off drug for more 
extended time periods. In addition to diurnal arousal effects, carry-over effects also appear to affect 
the 15–30 Hz component as a broad ∼15–30 Hz peak also remains present in this range for the shortest 
washout baselines in Subject 1 (4 hr; Figure 4D). The main findings of suppression of ∼6–10 Hz activity 
and increase of ∼15–30 Hz activity with zolpidem administration showed a general robustness across 
all three subjects and in Subjects 1 and 2 across separate assessments of ON and OFF drug doses 
(Tables 1 and 2).
Consistent patterns of EEG dynamics across Subjects 1 and 2 are also observed over the 2.5–3 hr 
course of each dose, as shown in Figure 5. In both subjects, the increase in high frequency power 
has two phases: maximal increases in power ∼15–30 Hz occur within the first 30–40 min, and this 
is followed by an attenuation of power and narrowing of frequency range to ∼20–30 Hz. By 2 hr 
after dosing, the enhanced high-frequency power has noticeably decayed. In contrast, both subjects 
show suppression of low-frequency power beyond this point (up to 3 hr in subject 1, and up to 4 hr in 
subject 2), suggesting that the prolonged effect on low-frequency activity may underlie the ‘carry-over’ 
effect. (Data were not collected for subject 3 beyond the first hour after zolpidem administration 
and similar analyses are thus not available).
Of particular interest is a finding observed in two posterior channels from subject 1 in one of 
the three transitions analyzed (dose two). As seen in the third spectrogram (bottom panel) shown in 
Figure 5A, the posterior channels CPz-POz reveal the appearance of a ∼10 Hz feature in the spectro-
gram around 1.25–1.5 hr after administration of the dose (green arrow). This feature of the CPz-POz 
spectrogram is distinct from the low frequency ∼7 Hz feature (red arrows) and high frequency 15–25 Hz 
feature (white arrows) seen in the other EEG channel spectrograms (Figure 5A). While not reproduced 
in other transitions, this feature suggests a possible restoration of the posterior alpha rhythm arising 
later in the course of ON drug state.
Effects of zolpidem on EEG coherence
To determine whether zolpidem administration altered the relationship between activity across cortical 
regions, we examined its influence on EEG coherence. Representative findings are shown in Figure 6A,B,C 
Figure 3. Power spectra (mean and 95% confidence intervals) estimated from selected EEG channel recordings across the head from all three subjects 
(A, B, and C). Red: average spectral power in the hour prior to each zolpidem dose. Blue: 20–60 min after the zolpidem dose. Narrow, low frequency 
spectral peaks are apparent in the pre-drug state that are attenuated in the hour post-dose. Beta range peaks (∼20–30 Hz) are apparent in all post-drug 
spectra. Changes in ∼6–10 Hz peak between conditions are significant by two-group test (‘Methods’; Table 1).
DOI: 10.7554/eLife.01157.010
The following figure supplements are available for figure 3:
Figure supplement 1. Significance testing of power across frequencies comparing the OFF and ON zolpidem states for Subject 1, transition 1 (baseline 
vs first hour) is summarized using two-group test (see ‘Methods’; Bokil et al., 2007 for further methods). 
DOI: 10.7554/eLife.01157.011
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Figure 4. Power spectra from midline channels for subjects 1 and 2 across multiple transitions from a washout baseline 
to ON drug state. Eyes open, awake epochs selected from one hour prior to 1 hr subsequent to each dose (Red) 
are shown and compared to 20–60 min after the zolpidem dose (Blue). Changes in ∼6–10 Hz peak between conditions 
are significant by two-group test (Tables 1 and 2).
DOI: 10.7554/eLife.01157.012
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(and Figure 6—figure supplement 1) for intra-hemispheric coherence, and in Figure 7 for inter-
hemispheric coherence(and Figure 7—figure supplement 1). Consistently across subjects, the OFF 
drug state was associated with a coherence peak range 0.6–0.8 at ∼6–10 Hz , the same range as the 
low-frequency power peak (p<0.05, two-group test). Zolpidem administration reduced the level of 
coherence for most channels to the range 0.3–0.5. In subjects 1 and 2, this was typically accompanied 
by an increase in coherence in the range of the high-frequency power peak (20–30 Hz). These changes 
are most prominent in the transitions following the longest washout periods for Subjects 1 and 2 
(Doses one to three).
Discussion
Paradoxical behavioral facilitation in response to zolpidem in severely brain-injured subjects with 
disorders of consciousness is well-documented, but relatively rare, with only one of 15 subjects 
identified in a prospective study (Whyte and Myers, 2009). Here we studied three such patients with 
disparate etiologies of brain injury, who had very different underlying patterns of structural brain injury and 
mechanisms of widespread neuronal death and disconnection. Despite these differences, quantitative 
EEG analysis revealed strikingly consistent dynamical signatures of brain dynamics in the resting awake 
state, and how these dynamics were affected by zolpidem. In all subjects, resting EEG power spectra 
in the baseline state revealed an abnormal peak at ∼6–10 Hz and high coherence in this same frequency 
range across intra- and inter-hemispheric brain regions. Behavioral activation with zolpidem reliably 
attenuated ∼6–10 Hz power and coherence in all subjects and associated with an increase in power at 
∼15–30 Hz. These findings suggest a fundamental similarity in the dynamics of brain states that are 
poised to elicit a zolpidem response. Below we propose a physiological basis for these common resting 
Figure 5. Time-frequency analysis of selected EEG channels from Subject 1 (A) and Subject 2 (B). Frontal and posterior midline channels, for both 
subjects demonstrate a low frequency peak in power (red arrows) during the hour prior to zolpidem administration attenuates within the first 10–15 min 
after the drug is given. This corresponds to the time period when the subject begins to manifest improved behavioral function. Concomitant with the 
attenuation of the low frequency peak, there appears a broader ∼15–25 Hz peak during the 30 min after the drug is given (white arrows), which narrows 
and reduces attenuates slowly over the next 2–3 hr. In Subject 1 (A), a ∼10 Hz peak appears approximately 1 hr into the post-dose period in CPz-POz 
channel (green arrow).
DOI: 10.7554/eLife.01157.013
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state dynamics identified by our EEG findings in the OFF drug state that show specific correspondence 
with known physiological processes. We further discuss a key prediction of this model: that changes 
observed in EEG spectral content during activation in the ON drug state will covary with the degree 
of structural and functional deafferentation of the cerebral cortex.
It is important to note that we are stopping short of proposing that a 6–10 Hz spectral peak with 
high spatial coherence is a predictor of zolpidem responsiveness. We suspect that the apparent rarity 
of the zolpidem response is not due to the incidence of this EEG feature (which is unknown), but to 
other factors, such as the 50-fold variations of GABA receptor subtype expression in the human 
population (Kang et al., 2011). Testing these ideas, however, goes far beyond the scope of the present 
study, as it would require a large structured, prospective, randomized clinical trial (Whyte and Myers, 
2009). We argue below, however, that these EEG findings may be a general marker of a recruitable 
reserve that in principle may be recruited by other neuromodulatory interventions (Schiff, 2010), 
and not just zolpidem.
Proposed cellular mechanisms underlying broadly coherent, low frequency 
oscillations observed in the OFF zolpidem state
As a result of diverse mechanisms of injury, all three severely brain-injured subjects suffered wide-
spread neuronal death and consequent deafferentation of many neurons across the cerebral cortex 
and subcortical structures. The implications of severe deafferentation of cortical neurons for EEG 
dynamics can be estimated by comparing two extremes: completely de-afferented ‘slabs’ of cortical 
tissue, and normal cortical tissue. In the former case (in vivo studies of completely deafferented ‘slabs’), 
neocortical neurons typically have an intracellular potential of ∼-70 mV and the dominant frequency of 
activity measured in far field potentials is ∼1 Hz (Timofeev et al., 2000). Intact, fully connected 
neocortical neurons have an average membrane potential in active wakeful states, that ranges 
from ∼−65 to −55 mV (Steriade, 2001) and the dominant frequency of far-field potentials is in the 
8–12 Hz range. Given these benchmarks it is reasonable to assume that in our patient subjects, 
all with very significant but incomplete deafferentation, that average membrane potentials are 
intermediate between these conditions. In this context, the prominent low frequency peaks seen across 
Figure 6. (A). Intra-hemispheric coherences (subject 1). Pre-drug coherence peaks at 6–10 Hz. This peak is attenuated in the hour after the drug is given. 
Changes in ∼6–10 Hz peak between conditions are significant by two-group test (‘Methods’; Figure 6 Figure Supplement 1). (B) (subject 2). 
Intra-hemispheric coherences (subject 2). Pre-drug coherence peaks are evident at ∼ 6–10 Hz. This peak is attenuated in the hour after the drug is given. 
(C) (subject 3). Intra-hemispheric coherences (subject 3). Pre-drug coherence peaks at ∼ 6–10 Hz. This peak is attenuated in the hour after the drug is given.
DOI: 10.7554/eLife.01157.014
The following figure supplements are available for figure 6:
Figure supplement 1. Significance testing of intra-hemispheric coherences for Subject 1, transition 2 (baseline vs first hour) is summarized using two-group 
test (see ‘Methods’; Bokil et al., 2007 for further methods). 
DOI: 10.7554/eLife.01157.015
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the power spectra from anterior EEG channels and across different OFF drug baselines of ∼7.4 Hz 
are notable for comparison to findings from in vitro studies of spontaneous oscillations generated by 
neocortical pyramidal cells. Silva et al. (Silva et al., 1991) identified that nearly identical frequencies 
of sustained firing lasting over seconds (7.4 Hz SD +/−0.6) are produced by layer V neocortical pyramidal 
cells in response to very brief (4 ms) current pulses. These sustained oscillations could be initiated 
under physiologic conditions in vitro that maintain intrinsic membrane potentials near firing threshold 
Figure 7. Inter-hemispheric coherences all three subjects. Pre-drug coherence peaks at 6–10 Hz are seen in frontal 
and posterior channels comparisons for all subjects. This peak is attenuated in the hour after the drug is given. 
Changes in ∼6–10 Hz peak between conditions are significant by two-group test (see ‘Methods’; Figure 7—
figure supplement 1, for Subject 1 coherences for example of coherence changes across all channel pairs in 
single dose).
DOI: 10.7554/eLife.01157.016
The following figure supplements are available for figure 7:
Figure supplement 1. Significance testing of inter-hemispheric coherences for Subject 1, transition 2 (baseline vs first 
hour) is summarized using two-group test (see ‘Methods’; Bokil et al., 2007 for further methods). 
DOI: 10.7554/eLife.01157.017
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at ∼−60–65 mV (Silva et al., 1991). As seen in Tables 1 and 2, an average center frequency of 7.4 Hz 
(∼SD +/−0.6) characterizes all but one of nine separately measured baselines across the anterior 
EEG channels of Subjects 1 and 2.
Thus, we propose that the markedly deafferented conditions of cortical neurons in the reduced 
slice preparation may reasonably approximate the markedly deafferented state of the cortex in our 
three subjects and that self-sustained intrinsic membrane oscillations arising from Layer V pyramidal 
neurons triggered by random synaptic background activity are the underlying mechanism for the 
origin of the ∼6–10 Hz activity present in the resting EEG at baseline. In the slice preparation, increases 
in membrane depolarization with stronger and more sustained injected currents produced shifts of 
these intrinsically generated oscillatory firing patterns toward higher frequencies (up to 12 Hz) when 
kept below firing threshold (Silva et al., 1991) indicating that a wider range of frequencies beyond 
7.4 Hz could in principle still reflect such pathologically driven oscillations (and in Subject 3 the resting 
oscillations tend to be at higher frequencies as shown in Figures 1 and 3C). Moreover, fully depolarizing 
these neurons in the slice results in similar shifts to ∼15–30 Hz firing rates (Silva et al., 1991).
If the intrinsic properties of partially de-afferented cortical tissue accounts for the peak of EEG 
activity in the 6–10 Hz range, then what could account for its high levels of spatial coherence? We 
propose that this coherence arises from a simple straightforward dynamical mechanism: the ‘Huygens’ 
clock principle’ (refer to Huygens, 1665; Rosenblum and Pikovsky, 2003). According to this principle, 
when oscillators with similar frequencies interact weakly, stable synchronization around a consensus 
frequency is the generic result. Here, we hypothesize that the net effects of residual Layer V output 
neurons (efferent to other cortical regions either directly or via subcortical structures) constitute a weak 
coupling. The predicted result is widespread coherence of cortical columns at a consensus theta 
frequency (∼7.4 Hz), as we in fact observe in all three subjects.
We speculate that our model for common baseline EEG dynamics may also account for other 
widespread rhythmic oscillations that are described in the cardiac arrest and other types of severe anoxic 
brain injury. These oscillations are in the alpha (Young et al., 1994) and less commonly theta (3–7 Hz) 
frequency range. Slower frequencies and lack of a change in frequency in response to sensory stimulation 
are associated with worse outcomes (Young et al., 1994), consistent with the notion that this activity 
results from de-afferentation, and the dominant frequency range indexes its severity.
However, we do not propose that all forms of pathological rhythmic activity arise from this 
mechanism, only to those in which the structural brain injuries are severe and diffuse. Theta (3–7 Hz) 
activity has also been reported in patients with focal cortical abnormalities or neuropsychiatric disorders 
without widespread neuronal loss or disconnection. For example, somewhat similar increases in theta 
power observed in the resting MEG signal recorded from patients with Parkinson’s disease, obsessive 
compulsive disorder and other syndromes have been proposed to arise in the setting of less severe 
deafferentation and disfacilitation of thalamic neurons producing a ‘thalamocortical dysrhymia’ syndrome 
(Jeanmonod et al., 1996; Llinás et al., 1999). These findings are correlated with theta frequency 
bursting identified in the thalamus (driven by de-inactivation of low-threshold T-type calcium channels 
(Jeanmonod et al., 1996)) of patients with Parkinson’s disease or central pain (Jeanmonod et al., 
1996; Llinás et al., 1999) who lack broad global cerebral deafferentation that characterizes our 
subject population with disorders of consciousness.
The distinction between global and focal injuries leading to rhythmic theta activity is important 
because these scenarios predict opposite effects on locally measured EEG activity in the 15–30 Hz 
range. Specifically, experimental and clinical studies of thalamocortical dysrrhythmia link abnormal 
increases in theta power to coincident abnormal increases 15–30 Hz activity produced by lateral 
inhibition in the cortex (‘edge effect’, Llinás et al., 1999; Llinás et al., 2005). Of note, the linkage 
of elevated 4–10 Hz and 15–30 Hz activity has been observed in a study of a zolpidem responsive 
stroke patient subject (Hall et al., 2010). Hall et al.(2010) studied MEG signals in a fully conscious, 
alert, and cognitively normal patient subject with mild aphasia and diminished sensorimotor inte-
gration ; these investigators reported that zolpidem administration produced similar changes of power 
suppression in co-localized areas of abnormally increased 4–10 Hz activity and increased 15–30 Hz 
activity in the resting MEG signal measured near the boundaries of a large stroke lesion within the 
damaged hemisphere. This suppression of increased high frequency power with zolpidem is exactly 
opposite to the changes observed in ∼15–40 Hz power in our subjects and indicates that a dif-
ferent mechanism underlies the changes seen in the present study, compared to that underlying 
the resting MEG activity in the Hall et al. subject (Hall et al., 2010). In the latter subject, global 
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cerebral structures, including both thalami, remained intact and the patient’s state of consciousness 
was normal (and there also was no history of a preceding disorder of consciousness). Moreover, in the 
Hall et al. study, no increases were observed in ∼15–40 Hz power outside of MEG channels with 
abnormal 3–7 Hz power (where ∼15–40 Hz suppressed with zolpidem administration). Since the ele-
vated theta and beta activity seen in the Hall et al. study was focal, it is more likely to be due to bursting 
of a localized set of deafferented thalamic neurons (i.e., thalamocortical dysrhythmia), than to wide-
spread cortical de-afferentation.
To produce thalamocortical dysrhythmia, low-threshold T-type calcium channels must be de-
inactivated (Jeanmonod et al., 1996; Llinás et al., 1999, 2005). This is far more probable to arise 
in this setting with a more locally deafferented thalamus in largely structurally intact brain. Taken 
together with the model proposed above, the distinct pattern of spectral changes observed in the 
Hall et al. patient leads to a prediction concerning the substrate of the pathological ∼3–7 Hz EEG 
oscillations in patients with severe brain injuries. In our subjects—with a widely coherent theta rhythm—
we expect that thalamic activity is severely suppressed and not generating widespread bursting 
activity. In contrast, when focal ∼3–7 Hz and ∼15–40 Hz oscillations coexist (as in the Hall et al. patient 
[Hall et al., 2010]), we hypothesize that the thalamus is not globally suppressed, and that instead, 
there is bursting due to focal thalamic deafferentation. The former expectation is supported by metabolic 
imaging studies in Subject 2, (Figure 8, Table 3), and other studies in awake severely brain-injured 
subjects that included direct measurement of thalamic activity that demonstrated loss of central 
thalamus firing activity (Giacino et al., 2012).
In addition to the thalamocortical dysrhythmia model of 6–10 Hz activity, other theoretical models 
of the expression of these rhythms in the corticothalamic system exist based on network dynamics 
(e.g., Ching et al., 2011; Drover et al., 2011; Hughes et al., 2004; Robinson et al., 2002). However, 
these models do not include gross alterations in physiological profiles of neurons in severely-injured 
brains with average neuronal membrane potentials remaining well below firing thresholds and likely 
do not capture the relevant physiological conditions present in our subjects. While an intrinsic cortical 
mechanism appears to be sufficient to account for our observations, such independent or interacting 
contributions of network mechanisms linked to thalamocortical projections ultimately cannot be con-
clusively excluded.
Proposed ‘mesocircuit’ mechanism underlying behavioral facilitation and 
changes in EEG resting dynamics observed in the ON zolpidem state
We next consider possibilities for how zolpidem might reverse the marked down-regulation of anterior 
forebrain activity. Two studies have demonstrated increases in cerebral perfusion and metabolism in 
zolpidem responsive subjects with disorders of consciousness (Brefel-Courbon et al., 2007; Nyakale 
et al., 2010). Brefel-Courbon et al.(2007) reported broad activation of FDG-PET signal with zolpidem 
in a patient remaining chronically in minimally conscious state who recovered speech, swallowing and 
ambulation reliably with zolpidem administration. 
These changes were marked and bi-hemispheric, 
demonstrating broad metabolic increases across 
the frontal lobes, striatum and thalami of both 
hemispheres (Subject 2 studied here a ∼50% reduc-
tion in global metabolic rates and relatively reduced 
frontal, striatal and thalamic metabolic expression 
consistent with this earlier report as shown in 
Figure 8). Local increases in blood flow within these 
same anterior forebrain regions have also been 
reported in the dominant hemisphere of a stroke 
patient who recovered fluent speech with zolpi-
dem administration (Cohen et al., 2004).
A‘mesocircuit’ model has been proposed to 
account for the mechanisms of action of zolpidem 
in the context of marked down-regulation of the 
anterior forebrain in the severely injured brain and 
restoration of activity across the anterior forebrain 
during recovery (Brown et al., 2010; Schiff, 2010). 
Figure 8. FDG-PET measured cerebral metabolism 
OFF and ON zolpidem for Subject 2. A marked 
increase in global cerebral metabolic rate is seen with 
zolpidem administration, average increase is 1.97 times 
OFF baseline across cerebral structures (see ‘Methods’ 
and Table 3 for regional differences in metabolic rates 
for selected areas).
DOI: 10.7554/eLife.01157.018
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Briefly, this mesocircuit model incorporates the basic 
observation that all severe brain injuries produce diffuse 
disfacilitation across corticothalamic systems arising from 
widespread disconnection or neuronal death (Adams 
et al., 2000; Maxwell et al., 2006). As a consequence 
of their broad and widespread point to point connec-
tions, neurons in the central thalamus are progres-
sively more deafferented with severity of structural brain 
injuries (Maxwell et al., 2006). Reduction of corticostri-
atal, thalamocortical and thalamostriatal outflow fol-
lowing multi-focal deafferentation and loss of neurons 
across the corticothalamic system likely also results in 
conditions of sufficient loss of afferent input to the 
medium spiny neurons (MSNs) of striatum to prevent 
these neurons from reaching firing threshold because of their requirement for high levels of synaptic 
background activity (Grillner et al., 2005). Loss of active inhibition from the striatum in turn is expected 
to result in release of tonic activity from neurons of the globus pallidus interna (GPi) that will provide 
an active inhibition to their synaptic targets including relay neurons of the already strongly disfacili-
tated central thalamus and possibly also the projection neurons of the pedunculopontine nucleus (Rye 
et al., 1996). Collectively, these effects are expected to produce very broad reductions in global cere-
bral synaptic activity as reflected in very low cerebral metabolic rates typically measured in severe 
brain injuries producing disorders of consciousness (reviewed in Laureys and Schiff, 2012). The main 
prediction of this model is that across all etiologies of structural injury, metabolic and functional down-
regulation of the anterior forebrain should be prominent. The dominance of the ∼7.4 Hz activity across 
fronto-central EEG channels observed here provide support for this prediction.
A primary proposed activating effect of zolpidem is suppression of increased firing of the GPi via a 
direct effect of zolpidem on GABA-A alpha 1 subtype receptors which are present on all neuronal cell 
types in the human globus pallidus interna (Waldvogel et al., 1999). Zolpidem can also be linked 
directly to the selective binding of GABA-A alpha 1 receptor subtypes in the neocortex, where it 
may increase thalamocortical and thalamostriatal outflow indirectly as a result of activation of cortical 
inhibitory interneuronal networks (McCarthy et al., 2009). In addition, zolpidem may activate the 
striatum where GABA-A currents facilitate alpha and beta (∼8–30 Hz) rhythms within the striatum and 
normal MSN function (McCarthy et al., 2011). Finally, a direct stimulatory action of GABAergic agonist 
at the pyramidal cell axon could produce excitation and persistent gamma-frequency oscillations (Traub 
et al., 2003). Collectively, all of these potential mechanisms of zolpidem’s action would result in the 
marked increase of thalamocortical and thalamostriatal outflow, restoration of corticothalamic and 
corticostriatal outflow, as well as suppression of tonic inhibition of the central thalamus and possibly 
the PPN by the GPi.
Zolpidem induced behavioral facilitation and EEG activation in patients has been proposed to 
directly link to a phenomena generally observed in anesthesia known as ‘paradoxical excitation’ which 
arises with propofol and other anesthetics (Brown et al., 2010). In the context of anesthesia, broad 
reductions of background synaptic activity occur during initial sedation. During paradoxical excitation 
normal subjects demonstrate a brief period of agitation and increased power in the 15–30 Hz frequency 
range after the initial quieting with light sedation. Paradoxical excitation is more common with 
GABAergic agonists (Brown et al., 2010) and the phenomenon may reflect a similar process of release 
of thalamocortical outflow. A consistent but less prominent shift of fronto-central activity toward 
increased beta range frequencies (∼15–30 Hz) is initiated by zolpidem in the EEG of awake normal 
subjects receiving the drug but it is not sustained for more than 30 min before returning to baseline 
(Patat et al., 2004). Thus, it can be expected that all patients administered zolpidem will show similar 
initial dynamical changes in EEG the early period after drug administration (∼30 min). However, in 
those brain-injured patients who show behavioral facilitation with zolpidem this initial shift of ‘paradoxical 
excitation’ is sustained and evolves over time as shown in Figure 5 and is associated with further dynam-
ical changes (narrowing of increased activity in the 20–35 Hz range). The observations of propofol and 
zolpidem induced increases in 15–30 Hz activity shows that an initial shift of power in this range is 
expected in all subjects, it remains unclear how this initial change interacts with the overall increase in 
cortical activation (as indexed by the loss of the ∼7.4 Hz activity) and remains self-sustaining.
Table 3. Percent change in regional 
standardized uptake values with 
administration of zolpidem
Region Left(%) Right(%)
Mesial frontal 139 146
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Effective behavioral facilitation likely involves a significant recruitment of cerebral activity across 
many other cortico-cortical and cortical-subcortical pathways that may become self-sustaining and 
further activating. This interpretation anticipates other contributions from brain arousal systems and 
ongoing activity within the cerebrum in maintaining the power distribution in the ∼20–30 Hz range 
across the frontal-temporal and central-parietal regions as observed for both Subjects studied over 
hours (refer to Figure 5). Such engagement of the plurality of arousal systems in ongoing wakeful 
behaviors is a powerful arousal stimulus as demonstrated experimentally even in animals with primary 
deficits in the orexin wake promoting systems of the hypothalamus (España et al., 2008). The evident 
carry over effects of continued zolpidem use in Subject 2 noted above suggests that restoration of 
behavior allows additional benefits to be harnessed in drug responders. However, the washout periods 
here were not varied experimentally, so a more rigorous assessment of this hypothesis awaits future 
work. The appearance of several posterior EEG channels with increased average center frequency 
in the 9–10 Hz in both subjects 1 and 2 in association with shorter washout intervals (Tables 1 and 2) 
is also consistent with a time-evolving recruitment of activity; expression of more normal patterns 
of organized rhythms may require the sustained cortical activation over time, with shorter dosing 
intervals allowing the effects of each dose to build up background brain activity.
Methods
Subjects 1 and 2 were admitted to the inpatient neurology unit at New York Presbyterian Hospital—Weill 
Cornell Campus for several days under an IRB-approved natural history study of recovery following severe 
brain injuries. For each subject, 24 hr video EEG were obtained while they received a continuation of their 
at home medication regimens. Zolpidem 10 mg was administered crushed, in solution via syringe one 
to three times daily by mouth for subject 1 and via percutaneous endoscopic gastrostomy (PEG) tube for 
subject 2. The resultant EEG recordings were reviewed for each subject, and EEG segments of 3 s duration 
that were artifact-free in the analyzed channels were identified extracted from the hour before and 
each of the first 4 hr after each administration of the drug, for each administration studied (four doses 
in Subject 1, five doses in Subject 2). Subject 3 underwent quantitative behavioral evaluations and 
study with high density EEG in their home (performed by investigators from University of Liege, 
Belgium) before and 20 min after taking zolpidem. Zolpidem 10 mg was administered per nasogastric 
tube. PET studies for ON and OFF drug states were obtained for Subject 1 and 2 but only reported 
for Subject 2 in ‘Clinical histories’ here as Subject 1’s OFF drug study was severely motion corrupted 
and reliable measurements could not be obtained. For subject 2, FDG-PET studies in both the zolpidem-
naive state and 30–90 min after administration of the drug were obtained 24 hr apart at the same time 
of day with equivalent fasting serum glucose levels of 81 and 80 mg/dl (see below for details). All 
procedures done in this study were in compliance with the Declaration of Helsinki.
Video EEG data acquisition
Subjects 1 and 2 were recorded continuously over 24 hr periods (with occasional interruption for 
imaging tests) using video EEG (vEEG) at a sampling rate 1024 Hz for subject 1 and 200 Hz for subject 
2 using an XLTEK data acquisition system (Xltek-Tech, Ltd., Oakville, Ontario, Canada LH65S1). Silver 
chloride scalp electrodes (19 electrodes for subject 2, 35 electrodes for subject 1) were affixed with 
collodion according to a modified international 10–20 system of electrode placement, with the lead at 
the FPz location as the ground reference. Impedance checks were carried out periodically to ensure 
impedance less than 5 kiloOhms in all leads.
Subject 3’s EEG recordings were acquired using a 256 active electrode high-density EEG system 
(Electrical Geodesics) sampled at 500 Hz and referenced for acquisition purposes to Cz (the EEG 
acquisition system default setting). Videotaped recordings were acquired simultaneously and syn-
chronously to the EEG data to confirm the patients’ behavior.
Data analysis
For Subjects 1 and 2 video EEG recordings were manually reviewed on an XLTEK NeuroWorks EEG 
reviewing station and epochs of 3 s duration without movement artifact were identified that fell within 
60 min prior to each recorded zolpidem dose or between 20 and 60 min after each dose. Channels 
with perceptible muscle artifact were excluded from primary analysis. Additional epochs of 3 s duration 
with no movement artifact and minimal muscle artifact were identified during the 4 hr subsequent to 
each zolpidem dose.
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All signals were detrended and line noise removed using standard MATLAB functions. We then 
estimated power spectra using the multi-taper method (Thomson, 1982; Thomson and Chave, 1991; 
Mitra and Pesaren, 1999; Mitra and Bokil, 2007). With five tapers, the effective frequency resolution 
obtained was 1.7 Hz for 3 s epochs and 2.5 Hz for 2 s epochs. The resulting power spectra were then 
averaged for all epochs in a condition, and 95% confidence intervals were computed via taper-based 
jackknife techniques (Thomson and Chave, 1991; Mitra and Bokil, 2007). All spectral estimates were 
calculated using Chronux functions, written in MATLAB (Goldfine et al., 2011).
Peaks in power were identified by the presence of a maximum in the spectrum within the frequency 
range of interest (e.g. 6–12 Hz for low frequency peaks).
Time-varying power spectra (spectrograms, Figure 5) were derived as follows: for each minute 
(60 s) of data recorded between one hour prior to and 3–4 hr after zolpidem administration, an epoch 
of 3 s duration with the least artifact was selected. Power spectra were then estimated as described 
above for each epoch, and averaging across epochs was not performed.
Coherences were estimated as cross-covariance of the individual signals, normalized by the 
geometric mean of their power spectra. Nine tapers were used, providing an effective frequency 
resolution of 3 Hz.
Significance testing
To determine significant changes between EEG samples obtained from ON and OFF drug conditions we 
used the Two Group Test (TGT, 12), as implemented by the Chronux toolbox routine, two_group_test_
spectrum (http://www.chronux.org), with a cutoff of p=0.05 by the jackknife method. Because spectral 
estimates within 2 Hz of each other are correlated by the taper functions, a difference identified by the TGT 
was only considered significant if it was present for all frequencies contiguously over a range greater than 
2 Hz. TGT was applied for all comparisons of spectral power and coherence (Goldfine et al., 2011) shown 
here (see Tables 1 and 2 for power significance testing of suppression of low frequency peaks for all 
channels and doses in Subjects 1 and 2, Figure 2—figure supplement 1; Figure 6—figure supplement 1 
for example of coherence significance testing across all channel pairs).
Clinical histories
Subject 1
A 45 year old man suffered traumatic brain injury due to a fall from a second floor ladder to a concrete 
surface 5 years prior to the study. At the time of the study, this subject varied in level of behavioral func-
tion from a total score on the Coma Recovery Scale-Revised (CRS-R) of 10–14 at baseline to a reliable 
score of 23 with zolpidem administration (the highest level of function measured by this instrument, a 
level consistent with emergence from MCS). At baseline (off zolpidem) the subject could stand and trans-
fer from bed to wheelchair with assistance but made no attempts at verbal communication with or with-
out prompting. He followed simple commands only intermittently and could spontaneously demonstrate 
the functional use of a napkin but no other commonly used objects (cup, toothbrush, comb). On zolpi-
dem the patient regained fluent spoken language, could accurately give his full name, read and write 
simple words and phrases as well as demonstrate the functional use of common objects as well demon-
strating a variety of higher level executive motor skills (e.g., accurate construction of arbitrary block 
configuration with up to five different block design objects). On zolpidem the subject responded appro-
priately to wide range of simple yes/no questions (e.g., ‘am I pointing to my nose?, do you live in 
Hawaii?’) and general knowledge questions. Additional testing with Mississippi Aphasia Screening Test 
during two ON zolpidem periods demonstrated a maximum score of 57/100 items on this examination.
Subject 2
A 32 year old man remained in a minimally conscious state (MCS) for 2 years after a severe mixed 
traumatic and hypoxic-ischemic brain injury due to near drowning in a motor vehicle accident 9 years 
prior to the study. At 2 years after injury the subject had a first exposure to zolpidem and demonstrated 
recovery of spoken language and accurate communication with first dose. Following this observation 
the patient began a regime of three zolpidem doses daily around the time of meals as use of the 
medication allowed for sufficient control of deglutition and management of saliva to safely engage 
in oral feeding. This regime had continued over the 5 year period prior to these studies. Off zolpidem, 
the subject exhibited prolonged latency of responses to questions or commands, severe dysarthria 
and dysphagia. He had left-sided hemiparesis and spasticity with flexor posturing and a 1–1.5 Hz 
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resting tremor of the right upper extremity. After receiving zolpidem the subject was alert, attentive 
and initiated interaction frequently, with improved verbal fluency and articulation, and with shortened 
latency of response. He organized complex goal-directed movements of both upper extremities 
(e.g., formulating an accurate ‘knuckleball’ baseball pitch using the right hand and arm, throwing 
the ball across the room). He demonstrated reduced spasticity in the left upper extremity, marked 
reduction of tremor in the right upper extremity and was able to manipulate small objects such as a 
pen, spoon and a hairbrush with the right hand. Both loss of oral feeding capacity and spasticity of the 
right extremity returned after each zolpidem dose had worn off.
Subject 3
A 55 year old woman suffered a spontaneous hemorrhagic cerebral vascular accident. Prior to zolpidem 
exposure the patient demonstrated marked arousal impairment and required intensive stimulation to 
maintain an eyes open awake state. The patient could with vigorous stimulation speak spontaneously 
emitting only halting expression (stammering, missing words, and frequent phonological and semantic 
errors). She was confused at baseline and exhibited spatio-temporal disorientation . She also presented 
visual hallucinations (e.g., ‘there is a boy running in the room’) and repetitive movements mimicking 
activities of daily living but out of context (e.g., sewing in the air). The patient was able to demonstrate 
reproducible responses to verbal command (e.g., squeeze hand) and sustain visual fixation to people 
in the room but did not demonstrate visual pursuit. Automatic motor behavior such as scratching of 
nose and passive manipulation of objects occurred spontaneously (e.g., rolling of a ball in the hand). 
She localized nociceptive stimuli. A yes/no communication system using gesture could be established 
but without accurate yes/no communication. Following zolpidem administration the patient shifted to 
an eyes open alert state and showed agitation. Her spontaneous speech rate increased and she formed 
understandable words in short phrases and initiated interpersonal interactions.
PET studies for Subject 2
To characterize resting brain metabolism on and off zolpidem, we performed 18-FDG-PET studies on 
days 2 and 3 for subject 1. This subject had received his last zolpidem dose more than 15 hr prior to 
the first study and approximately 30–60 min prior to the second study. Both studies were performed 
on a General Electric Discovery LS PET/CT system (General Electric Company, Fairfield, CT) using a 
standard resting condition in 2-dimensional (2D) mode. Thirty-five slices were acquired in dynamic 
high-sensitivity emission mode (matrix size = 128 × 128 × 35, axial field of view = 25 cm, 4.25-mm slice 
thickness). Attenuation correction and anatomical localization were achieved by performing a helical 
CT scan in the same session, the images from which were subsequently reconciled to the PET image.
Regions of interest were identified for mesial frontal cortex, lateral frontal cortex, head of the 
caudate, putamen, thalamus and calcarine cortex. We then calculated standardized uptake values 
(SUVs) for these regions, as well as globally for each condition. Regional SUVs were then normalized 
by global averages. Global metabolism increased by a factor of 1.97 on zolpidem in comparison 
to the off-drug state (Figure 8). There was an overall increase in anterior forebrain metabolism, with 
the largest percent increase occurring in the lateral frontal cortex.
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